#ISP-002
Urgent pilot report at 1938Z: ISP UUA /OV KISP/TM 1938/FLDURC/TP BCS3/SK BASES 002/RM RWY 06
September 27, 2026 at 7:40 PM
Urgent pilot report at 1919Z: ISP UUA /OV KISP/TM 1919/FLDURD/TP GLF5/SK BASES 002/RM RWY 06
September 27, 2026 at 7:22 PM
Urgent pilot report at 0047Z: ISP UUA /OV ISP/TM 0047/FLDURD/TP B737/TB MOD/RM + 25KTS AT 002 FOR RY 6
September 27, 2026 at 12:38 AM
Computer: irri2022-002
City: Denain
Country: FR 🇫🇷
State: Hauts-de-France
ASN + ISP: AS3215 Orange S.A.
VNC Resolver ID: 3188341969
November 12, 2024 at 8:33 AM
Computer: QEMU (VPS-002)
City: Frankfurt am Main
Country: DE 🇩🇪
State: Hesse
ASN + ISP: AS16276 OVH SAS
VNC Resolver ID: 1241045562
November 8, 2024 at 9:39 AM
Urgent pilot report at 1742Z: ISP UUA /OV ISP/TM 1742/FLDURD/TP B737/TB MOD TB @ 002/RM +10 KTS
May 6, 2026 at 5:44 PM
Urgent pilot report at 1620Z: ISP UUA /OV ISP/TM 1620/FLDURD/TP A320/RM LLWS +15 KT BLO 002
April 11, 2026 at 4:24 PM
Urgent pilot report at 1625Z: ISP UUA /OV ISPT/TM 1625/FLDURD/TP B737/SK BASES OVC 002/RM RWY 06 BA GOOD
March 7, 2026 at 4:28 PM
Urgent pilot report at 1846Z: ISP UUA /OV ISPT/TM 1846/FLDURD/TP A20N/SK OVC 002/RM RWY 24
December 29, 2025 at 6:48 PM
Urgent pilot report at 1803Z: ISP UUA /OV ISPT/TM 1803/FLDURD/TP B38M/SK OVC 002/RM RWY 24
December 29, 2025 at 6:04 PM
Urgent pilot report at 1802Z: ISP UUA /OV ISPT/TM 1802/FLDURD/TP SF50/SK OVC 002/RM RWY 24
December 29, 2025 at 6:04 PM
Urgent pilot report at 1708Z: ISP UUA /OV ISPT/TM 1708/FL002/TP TBM9/WV -10 KTS AOB 002
May 18, 2025 at 5:11 PM
Urgent pilot report at 1852Z: ISP UUA /OV ISP/TM 1852/FLDURD/TP A20N/RM LLWS -10KT 010 +10KT 002
March 2, 2025 at 6:57 PM
Immusoft Achieves FDA Designation for Groundbreaking Pediatric Disease Therapy ISP-002#USA#San_Francisco#Immusoft#MPS_II#ISP-002
Immusoft Achieves FDA Designation for Groundbreaking Pediatric Disease Therapy ISP-002
Immusoft has received FDA Rare Pediatric Disease designation for ISP-002, a revolutionary B cell therapy aimed at treating MPS II, a rare genetic disorder.
third-news.com
January 26, 2026 at 1:35 PM
Immusoft Celebrates FDA's Orphan Drug Designation for ISP-002 in Treating MPS II#USA#San_Francisco#Immusoft#MPS_II#ISP-002
Immusoft Celebrates FDA's Orphan Drug Designation for ISP-002 in Treating MPS II
Immusoft, a pioneering biotechnology firm, is making strides in treating MPS II with its ISP-002 therapy, now with FDA's Orphan Drug Designation.
third-news.com
December 15, 2025 at 1:24 PM
Immusoft's ISP-002 designated US orphan drug for MPS II | BioWorld - goo.gl/alerts/Qz1Qzb #GoogleAlerts
Immusoft’s ISP-002 designated US orphan drug for MPS II
Immusoft of CA Inc., a wholly owned subsidiary of Immusoft Corp., has announced that the FDA has granted orphan drug designation to ISP-002, the company’s investigational engineered B-cell therapy for...
goo.gl
December 17, 2025 at 1:51 PM